3:45 PM
 | 
Apr 18, 2014
 |  BC Extra  |  Company News

FDA briefing docs rebuff MoxDuo IR

FDA's Bob Rappaport said the agency's review team has been "unable to conclude that there is a safety benefit"...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >